<?xml version="1.0" encoding="UTF-8"?>
<p id="par0265">Preliminary data [
 <xref rid="bib0410" ref-type="bibr">82</xref>] included cases of 21 severe and critical pneumonia in COVID-19 confirmed patients who showed clinical and radiological improvement in 75.0 % (severe pneumonia) and 90.5 % (critical pneumonia) of participants. Lymphocyte count also returned to normal in 52.6 % of cases on day 5 of drug administration. All patients received 400 mg of intravenous Tocilizumab once, and three patients, due to persistent fever, received another 400 mg dose after 12 h.
</p>
